Switching to tenofovir alafenamide for nucleos(t)ide analogue-experienced patients with chronic hepatitis B: week 144 results from a real-world, multi-centre cohort study.

Eiichi OgawaMakoto NakamutaToshimasa KoyanagiAritsune OohoNorihiro FurusyoEiji KajiwaraKazufumi DohmenAkira KawanoTakeaki SatohKazuhiro TakahashiKoichi AzumaNobuyuki YamashitaNaoki YamashitaRie SugimotoHiromasa AmagaseMasami KuniyoshiYasunori IchikiChie MoritaMasaki KatoShinji ShimodaHideyuki NomuraJun Hayashinull null

Published in: Alimentary pharmacology & therapeutics (2022)

Switching to TAF remained effective and safe for up to 3 years. Given the increasing comorbidities related to ageing, it will be important to carefully follow the change in the lipid levels of patients with a prior TDF-based regimen.

Keyphrases

hepatitis b virus
antiretroviral therapy
randomized controlled trial
clinical trial
drug induced
placebo controlled